Carna Health Secures $8M for Global AI-Driven Kidney Care Expansion
January 11, 2026, 9:36 am
Carna Health, a Boston-based digital health pioneer, secured $8M in new funding. This capital infusion propels its advanced AI-driven Cardio-Kidney-Metabolic (CKM) platform. The company targets early chronic kidney disease (CKD) identification and comprehensive patient management. This strategic funding fuels significant global expansion initiatives. Key markets include the United States, Turkey, the Philippines, and the Dominican Republic. A pivotal partnership with Siemens Healthineers amplifies access to crucial point-of-care diagnostic testing. Carna Health is actively transforming global preventative kidney care and metabolic health through innovative digital solutions and strategic outreach.
Carna Health is reshaping global kidney care. The digital health company recently secured $8 million in funding. This capital boosts its advanced AI-driven CKM platform. The investment fuels a bold mission: revolutionize early detection and management of chronic kidney disease (CKD). Carna Health targets a silent epidemic affecting millions worldwide.
CKD often progresses unnoticed. Symptoms typically appear in late stages. At that point, treatment options narrow to dialysis or transplantation. Carna Health aims to close this dangerous identification gap. Its platform provides a low-friction screening infrastructure. This system works even in resource-limited environments. It ensures early intervention is possible.
The $8 million funding round drew diverse investors. Dr. Jay Rosan, Cenk Bekmezçi, Jose Pereyra, Mark Boulding, Brandon Salomon, Andrew Roosevelt, Jeff Lindsey, Joseph White, John Brooks, and Elvis Ndansi participated. Carna Health’s CEO, Dr. Salvatore Viscomi, also invested. This broad support underscores confidence in Carna Health’s vision and technology.
Funds will drive aggressive global expansion. Carna Health plans significant entry into the United States and Turkish markets. These regions represent critical battlegrounds against rising CKD rates. The company also extends its reach in other key territories.
Previous initiatives demonstrate Carna Health’s impact. A successful program in Cameroon screened 35,000 individuals. This showcased the platform's effectiveness in diverse settings. Now, the company launches new programs in the Philippines. It partners with major cities and healthcare systems there. A national initiative is also underway in the Dominican Republic. These efforts aim to bring preventative kidney care to vast populations.
The core of Carna Health’s innovation lies in its AI-driven platform. This technology supports early risk identification. It enables coordinated follow-up across connected metabolic diseases. The platform integrates testing solutions with advanced artificial intelligence. This enhances CKD screening, monitoring, and care management. It is a comprehensive solution.
A strategic agreement with Siemens Healthineers strengthens Carna Health's global reach. This partnership expands access to preventative kidney care worldwide. Siemens Healthineers’ global point-of-care diagnostics capabilities are crucial. They allow laboratory-grade testing in community settings. This integration is vital for accessible screening.
The AI doesn't just identify risk. It guides clinicians. The platform helps navigate complex care pathways. It ensures at-risk patients receive coordinated follow-up. This includes management for related metabolic conditions. The approach is holistic. It prevents disease progression. It improves patient outcomes.
Carna Health focuses on Cardio-Kidney-Metabolic (CKM) care. This recognizes the interconnectedness of these conditions. Heart disease, kidney disease, and metabolic disorders like diabetes often coexist. Managing them together offers superior patient benefits. The platform addresses this complex interplay.
The company's digital health solutions make quality healthcare more accessible. They reduce barriers to early diagnosis. They empower healthcare providers. They equip patients with vital information. This fosters proactive health management.
Carna Health is setting new standards in digital health. It champions preventative care. Its AI-driven technology offers precise, timely interventions. The global expansion targets areas with high unmet needs. This strategic growth makes a tangible difference. It saves lives. It improves quality of life.
The investment bolsters Carna Health’s capacity. It accelerates product development. It expands operational infrastructure. The goal is a transformative digital health platform. This platform broadens access to comprehensive CKD care. Early identification is key. Effective monitoring follows. Robust patient management completes the cycle.
Carna Health exemplifies healthcare innovation. It leverages cutting-edge AI. It forms strategic partnerships. It focuses on global reach. The company is not merely treating disease. It is actively preventing it. This proactive stance defines its mission. It defines its future impact.
The company's leadership remains committed. They push boundaries. They advance medical technology. Their vision is clear: a world where CKD is no longer a silent killer. Early detection changes the narrative. Coordinated care saves lives. Carna Health is making this vision a reality.
Carna Health is reshaping global kidney care. The digital health company recently secured $8 million in funding. This capital boosts its advanced AI-driven CKM platform. The investment fuels a bold mission: revolutionize early detection and management of chronic kidney disease (CKD). Carna Health targets a silent epidemic affecting millions worldwide.
CKD often progresses unnoticed. Symptoms typically appear in late stages. At that point, treatment options narrow to dialysis or transplantation. Carna Health aims to close this dangerous identification gap. Its platform provides a low-friction screening infrastructure. This system works even in resource-limited environments. It ensures early intervention is possible.
The $8 million funding round drew diverse investors. Dr. Jay Rosan, Cenk Bekmezçi, Jose Pereyra, Mark Boulding, Brandon Salomon, Andrew Roosevelt, Jeff Lindsey, Joseph White, John Brooks, and Elvis Ndansi participated. Carna Health’s CEO, Dr. Salvatore Viscomi, also invested. This broad support underscores confidence in Carna Health’s vision and technology.
Funds will drive aggressive global expansion. Carna Health plans significant entry into the United States and Turkish markets. These regions represent critical battlegrounds against rising CKD rates. The company also extends its reach in other key territories.
Previous initiatives demonstrate Carna Health’s impact. A successful program in Cameroon screened 35,000 individuals. This showcased the platform's effectiveness in diverse settings. Now, the company launches new programs in the Philippines. It partners with major cities and healthcare systems there. A national initiative is also underway in the Dominican Republic. These efforts aim to bring preventative kidney care to vast populations.
The core of Carna Health’s innovation lies in its AI-driven platform. This technology supports early risk identification. It enables coordinated follow-up across connected metabolic diseases. The platform integrates testing solutions with advanced artificial intelligence. This enhances CKD screening, monitoring, and care management. It is a comprehensive solution.
A strategic agreement with Siemens Healthineers strengthens Carna Health's global reach. This partnership expands access to preventative kidney care worldwide. Siemens Healthineers’ global point-of-care diagnostics capabilities are crucial. They allow laboratory-grade testing in community settings. This integration is vital for accessible screening.
The AI doesn't just identify risk. It guides clinicians. The platform helps navigate complex care pathways. It ensures at-risk patients receive coordinated follow-up. This includes management for related metabolic conditions. The approach is holistic. It prevents disease progression. It improves patient outcomes.
Carna Health focuses on Cardio-Kidney-Metabolic (CKM) care. This recognizes the interconnectedness of these conditions. Heart disease, kidney disease, and metabolic disorders like diabetes often coexist. Managing them together offers superior patient benefits. The platform addresses this complex interplay.
The company's digital health solutions make quality healthcare more accessible. They reduce barriers to early diagnosis. They empower healthcare providers. They equip patients with vital information. This fosters proactive health management.
Carna Health is setting new standards in digital health. It champions preventative care. Its AI-driven technology offers precise, timely interventions. The global expansion targets areas with high unmet needs. This strategic growth makes a tangible difference. It saves lives. It improves quality of life.
The investment bolsters Carna Health’s capacity. It accelerates product development. It expands operational infrastructure. The goal is a transformative digital health platform. This platform broadens access to comprehensive CKD care. Early identification is key. Effective monitoring follows. Robust patient management completes the cycle.
Carna Health exemplifies healthcare innovation. It leverages cutting-edge AI. It forms strategic partnerships. It focuses on global reach. The company is not merely treating disease. It is actively preventing it. This proactive stance defines its mission. It defines its future impact.
The company's leadership remains committed. They push boundaries. They advance medical technology. Their vision is clear: a world where CKD is no longer a silent killer. Early detection changes the narrative. Coordinated care saves lives. Carna Health is making this vision a reality.